Filtered By:
Vaccination: Influenza Vaccine
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 427 results found since Jan 2013.
Fight Aging! Newsletter, June 14th 2021
In conclusion, a number of high-income countries, changes in health expectancies over time have not kept pace with the growth in life expectancy. That is, people are living longer but disability and poor health are occupying an increasing proportion of later life. Our findings suggest that countries still need to make significant progress to achieve the WHO's Decade of Healthy Ageing goal of healthier, longer lives for all.
Progress on Understanding Why Human Growth Hormone Receptor Variants are Associated with Greater Longevity
https://www.fightaging.org/archives/2021/06/progress-on-understanding-why-human-gro...
Source: Fight Aging! - June 13, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Care of rheumatology patients during the lockdown in early 2020 : Telemedicine, delegation, patient satisfaction and vaccination behavior
CONCLUSION: Telemedical care within the framework of a telephone consultation is well-suited for selected patients. With respect to patient satisfaction the delegation of a telemedical consultation to an RFA is possible. There is a need for improvement with respect to the vaccination behavior.PMID:33974131 | PMC:PMC8111653 | DOI:10.1007/s00393-021-01005-3
Source: Zeitschrift fur Rheumatologie - May 11, 2021 Category: Rheumatology Authors: Thea Thiele Sonja Beider Henrik K ühl Gudrun Mielke Anna Holz Stefanie Hirsch Torsten Witte Kirsten Hoeper Anne Cossmann Christine Happle Alexandra Jablonka Diana Ernst Source Type: research
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
IJERPH, Vol. 18, Pages 3607: A Longitudinal Study Regarding the Health Profile of the 2017 South African Hajj Pilgrims
Conclusion: Our study indicates that a sizable proportion of South African pilgrims are elderly with underlying health conditions and most contract respiratory tract infections during and post Hajj. Our study highlights the need for systematic collection of prospective pilgrims’ demographics and health data and more attention to post-Hajj health follow-ups of pilgrims.
Source: International Journal of Environmental Research and Public Health - March 31, 2021 Category: Environmental Health Authors: Abdulaziz Mushi Yara Yassin Anas Khan Badriah Alotaibi Salim Parker Ozayr Mahomed Saber Yezli Tags: Article Source Type: research
Adverse events following yellow fever vaccination in immunocompromised persons
Rev Inst Med Trop Sao Paulo. 2021 Mar 1;63:e13. doi: 10.1590/S1678-9946202163013. eCollection 2021.ABSTRACTThis observational retrospective study conducted during an yellow fever (YF) outbreak in Sao Paulo, Brazil, in 2017-2018, describes adverse events (AE) following YF vaccination of immunocompromised persons. Risks and benefits of vaccination were individually evaluated by physicians. AE were assessed by phone call or electronic mail, 14 to 90 days after vaccination. Three hundred and eighty one immunocompromised persons received a full-dose of YF vaccine. Their age ranged from 1.4 to 89.3 years (median 50.8 years); 53%...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - March 3, 2021 Category: Tropical Medicine Authors: Amanda Nazareth Lara Karina Takesaki Miyaji Karim Yaqub Ibrahim Marta Heloisa Lopes Ana Marli Christovam Sartori Source Type: research
